Lesage Anne sold $765K of PHVS (indirect holdings)

Lesage Anne (Chief Early Development) sold 20,000 indirectly-held shares of Pharvaris N.V. (PHVS) at $38.27 ($0.77M total) on 2026-09-17.

Original reporting
SEC EDGAR · Lesage Anne
Published Sep 21, 2026, 7:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as reduced confidence.

02

Market read

A routine insider sale with modest size; limited trading relevance.

03

What to watch

Potential upcoming clinical data releases may offset the sale impact.

Relevance 5/10Novelty 4/10Timing: filed 2026-09-21

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Insider officer Lesage Anne sold 20,000 shares for $765,466, reducing her stake to 73,969 shares.

Expected impact

Possible modest downside of 2-3% in the near term.

Evidence & confidence

Sale size is modest relative to float, but insider status adds weight; market may react negatively.

Market effects

Minimal impact on the biotech sector; typical insider sale.

No significant regional effect.

Limited to investors tracking PHVS.

Counterpoint

The sale could be routine liquidity need, not a negative signal.

Key entities

  • Pharvaris N.V.

    Biotech firm listed on Nasdaq under PHVS.

  • Lesage Anne

    Chief Early Development officer at Pharvaris.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.